Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.62 -3.43% -0.02
CATB closed down 3.43 percent on Friday, November 16, 2018, on 59 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CATB trend table...

Date Alert Name Type % Chg
Nov 16 20 DMA Resistance Bearish 0.00%
Nov 16 MACD Bearish Signal Line Cross Bearish 0.00%
Nov 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Nov 16 New 52 Week Low Weakness 0.00%
Nov 16 BB Squeeze Ended Range Expansion 0.00%
Nov 16 Outside Day Range Expansion 0.00%
Nov 16 Lower Bollinger Band Touch Weakness 0.00%
Nov 15 Bollinger Band Squeeze Range Contraction -3.43%
Nov 15 NR7 Range Contraction -3.43%
Nov 15 BB Squeeze Started Range Contraction -3.43%

Older signals for CATB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
Is CATB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.38
52 Week Low 0.6
Average Volume 882,395
200-Day Moving Average 1.1817
50-Day Moving Average 0.726
20-Day Moving Average 0.6596
10-Day Moving Average 0.661
Average True Range 0.0464
ADX 18.49
+DI 12.5441
-DI 20.5128
Chandelier Exit (Long, 3 ATRs ) 0.5808
Chandelier Exit (Short, 3 ATRs ) 0.7392
Upper Bollinger Band 0.7038
Lower Bollinger Band 0.6154
Percent B (%b) 0.05
BandWidth 13.402062
MACD Line -0.0196
MACD Signal Line -0.0193
MACD Histogram -0.0003
Fundamentals Value
Market Cap 13.94 Million
Num Shares 22.5 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -0.36
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.71
Resistance 3 (R3) 0.71 0.69 0.70
Resistance 2 (R2) 0.69 0.66 0.69 0.69
Resistance 1 (R1) 0.65 0.65 0.64 0.65 0.68
Pivot Point 0.63 0.63 0.62 0.63 0.63
Support 1 (S1) 0.59 0.60 0.58 0.59 0.56
Support 2 (S2) 0.57 0.59 0.57 0.55
Support 3 (S3) 0.53 0.57 0.55
Support 4 (S4) 0.53